Tucker TJ - Search Results

1

Discovery and characterization of novel peptide inhibitors of the NRF2/MAFG/DNA ternary complex for the treatment of cancer.

Simov V, Altman MD, Bianchi E, DelRizzo S, DiNunzio EN, Feng G, Goldenblatt P, Ingenito R, Johnson SA, Mansueto MS, Mayhood T, Mortison JD, Serebrov V, Sondey C, Sriraman V, Tucker TJ, Walji A, Wan H, Yue Y, Stoeck A, DiMauro EF. Simov V, et al. Among authors: tucker tj. Eur J Med Chem. 2021 Nov 15;224:113686. doi: 10.1016/j.ejmech.2021.113686. Epub 2021 Jul 7. Eur J Med Chem. 2021. PMID: 34303079

2

Series of Novel and Highly Potent Cyclic Peptide PCSK9 Inhibitors Derived from an mRNA Display Screen and Optimized via Structure-Based Design.

Alleyne C, Amin RP, Bhatt B, Bianchi E, Blain JC, Boyer N, Branca D, Embrey MW, Ha SN, Jette K, Johns DG, Kerekes AD, Koeplinger KA, LaPlaca D, Li N, Murphy B, Orth P, Ricardo A, Salowe S, Seyb K, Shahripour A, Stringer JR, Sun Y, Tracy R, Wu C, Xiong Y, Youm H, Zokian HJ, Tucker TJ. Alleyne C, et al. Among authors: tucker tj. J Med Chem. 2020 Nov 25;63(22):13796-13824. doi: 10.1021/acs.jmedchem.0c01084. Epub 2020 Nov 10. J Med Chem. 2020. PMID: 33170686

3

A Series of Novel, Highly Potent, and Orally Bioavailable Next-Generation Tricyclic Peptide PCSK9 Inhibitors.

Tucker TJ, Embrey MW, Alleyne C, Amin RP, Bass A, Bhatt B, Bianchi E, Branca D, Bueters T, Buist N, Ha SN, Hafey M, He H, Higgins J, Johns DG, Kerekes AD, Koeplinger KA, Kuethe JT, Li N, Murphy B, Orth P, Salowe S, Shahripour A, Tracy R, Wang W, Wu C, Xiong Y, Zokian HJ, Wood HB, Walji A. Tucker TJ, et al. J Med Chem. 2021 Nov 25;64(22):16770-16800. doi: 10.1021/acs.jmedchem.1c01599. Epub 2021 Oct 27. J Med Chem. 2021. PMID: 34704436

4

Design of novel, potent, noncovalent inhibitors of thrombin with nonbasic P-1 substructures: rapid structure-activity studies by solid-phase synthesis.

Lumma WC Jr, Witherup KM, Tucker TJ, Brady SF, Sisko JT, Naylor-Olsen AM, Lewis SD, Lucas BJ, Vacca JP. Lumma WC Jr, et al. Among authors: tucker tj. J Med Chem. 1998 Mar 26;41(7):1011-3. doi: 10.1021/jm9706933. J Med Chem. 1998. PMID: 9544200

5

Discovery of 3-{5-[(6-amino-1H-pyrazolo[3,4-b]pyridine-3-yl)methoxy]-2-chlorophenoxy}-5-chlorobenzonitrile (MK-4965): a potent, orally bioavailable HIV-1 non-nucleoside reverse transcriptase inhibitor with improved potency against key mutant viruses.

Tucker TJ, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey G, Liu M, Miller M, Moyer G, Munshi V, Perlow-Poehnelt R, Prasad S, Reid JC, Sanchez R, Torrent M, Vacca JP, Wan BL, Yan Y. Tucker TJ, et al. J Med Chem. 2008 Oct 23;51(20):6503-11. doi: 10.1021/jm800856c. Epub 2008 Oct 1. J Med Chem. 2008. PMID: 18826204

6

Potent noncovalent thrombin inhibitors that utilize the unique amino acid D-dicyclohexylalanine in the P3 position. Implications on oral bioavailability and antithrombotic efficacy.

Tucker TJ, Lumma WC, Lewis SD, Gardell SJ, Lucas BJ, Baskin EP, Woltmann R, Lynch JJ, Lyle EA, Appleby SD, Chen IW, Dancheck KB, Vacca JP. Tucker TJ, et al. J Med Chem. 1997 May 23;40(11):1565-9. doi: 10.1021/jm970140s. J Med Chem. 1997. PMID: 9171866

7

Design of highly potent noncovalent thrombin inhibitors that utilize a novel lipophilic binding pocket in the thrombin active site.

Tucker TJ, Lumma WC, Mulichak AM, Chen Z, Naylor-Olsen AM, Lewis SD, Lucas R, Freidinger RM, Kuo LC. Tucker TJ, et al. J Med Chem. 1997 Mar 14;40(6):830-2. doi: 10.1021/jm960762y. J Med Chem. 1997. PMID: 9083470 No abstract available.

8

The design and synthesis of diaryl ether second generation HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs) with enhanced potency versus key clinical mutations.

Tucker TJ, Saggar S, Sisko JT, Tynebor RM, Williams TM, Felock PJ, Flynn JA, Lai MT, Liang Y, McGaughey G, Liu M, Miller M, Moyer G, Munshi V, Perlow-Poehnelt R, Prasad S, Sanchez R, Torrent M, Vacca JP, Wan BL, Yan Y. Tucker TJ, et al. Bioorg Med Chem Lett. 2008 May 1;18(9):2959-66. doi: 10.1016/j.bmcl.2008.03.064. Epub 2008 Mar 25. Bioorg Med Chem Lett. 2008. PMID: 18396399

9

Synthesis of a series of 4-(arylethynyl)-6-chloro-4-cyclopropyl-3,4-dihydroquinazolin-2(1H)-ones as novel non-nucleoside HIV-1 reverse transcriptase inhibitors.

Tucker TJ, Lyle TA, Wiscount CM, Britcher SF, Young SD, Sanders WM, Lumma WC, Goldman ME, O'Brien JA, Ball RG, et al. Tucker TJ, et al. J Med Chem. 1994 Jul 22;37(15):2437-44. doi: 10.1021/jm00041a023. J Med Chem. 1994. PMID: 7520079

10

Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted design.

Thompson WJ, Fitzgerald PM, Holloway MK, Emini EA, Darke PL, McKeever BM, Schleif WA, Quintero JC, Zugay JA, Tucker TJ, et al. Thompson WJ, et al. Among authors: tucker tj. J Med Chem. 1992 May 15;35(10):1685-701. doi: 10.1021/jm00088a003. J Med Chem. 1992. PMID: 1588551

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

62 results

Search Page